Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...
Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...
Fifteen-year follow-up from the S0016 trial suggests that some patients with advanced-stage follicular lymphoma may be cured with standard chemoimmunotherapy, according to Dr. Jonathan W. Friedberg, ...
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...
Investigators analyzed OS and PFS for patients with follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/ prednisolone (CHOP ...
The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...
Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.
Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma (NHL), has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell ...
The National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (Tepkinly, AbbVie) as a treatment option for adults with relapsed or refractory follicular lymphoma after two ...
Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.
Options remain for patients with relapsed/refractory follicular lymphoma, but tazemetostat was the only drug approved specifically for epithelioid sarcoma.
4d
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Bra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results